Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer - Concepedia

Concepedia

Publication | Open Access

Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer

DOI Full Paper Access

139

Citations

17

References

2010

Year

Diane Reidy‐Lagunes, Efsevia Vakiani, Marwan Fakih, Muhammad Wasif Saif, J. Randolph Hecht, Noah Goodman-Davis, Ellen Hollywood, Jinru Shia, Jonathan Schwartz, Kumari Chandrawansa,

Journal of Clinical Oncology

Abstract

IMC-A12 alone or in combination with cetuximab was insufficient to warrant additional study in patients with colorectal cancer refractory to EGFR inhibitors.

References

	Year	Citations

Page 1